

Index

Note: page numbers in *italics* refer to figures, those in **bold** refer to tables

- abdominal trauma
 - blunt 156–8
 - nephrectomy predictors 158–9
- Access Medicine 8
- acetoxyhydroxamic acid 195
 - ureteral stone expulsion 213–15
- acetylcholine 170
- acupuncture, nocturnal enuresis 398
- adriamycin, cisplatin combination in
 - metastatic bladder cancer 321, **322**, 323
- adverse events, major 30
- Agency for Healthcare Policy and Research (AHCPR) 41
- Agency for Healthcare Research and Quality (AHRQ) 40, 41
- alarms, nocturnal enuresis 394, 395–6, 397, 398–9
- alfuzosin
 - chronic prostatitis/chronic pelvic pain syndrome 113
 - premature ejaculation treatment 127
 - ureteral stone expulsion 196, **199**
- alkali citrate therapy 195
 - ureteral stone expulsion 211, 213, 215
- allocation concealment, RCTs 33
- allopurinol 195
 - ureteral stone expulsion 208, 211, **212**
- alpha-adrenergic antagonists
 - BPH symptom relief 94
 - chronic prostatitis/chronic pelvic pain syndrome 112–14
 - medical expulsive therapy 195–6, **197–200**, 201
 - premature ejaculation 126–7
 - ureteral stone expulsion 195–6, **197–200**, 201, 215
 - shock-wave lithotripsy adjuvant therapy 232–3
 - urinary incontinence in women 182
 - UTI prevention/treatment 72
- alprostadiol
 - erectile dysfunction 138–9
 - erectile function recovery after radical prostatectomy 140
 - mechanism of action 139
 - side effects 139
- American Academy of Family Physicians (AAFP), patient information 10
- American Association for the Surgery of Trauma (AAST), renal grade 156, 157, 158, 159
- American College of Cardiology (ACC), clinical practice guidelines 42
- American College of Chest Physicians (ACCP), guidelines for venous thromboembolism prevention 65, 66
- American College of Physicians (ACP) Journal Club 8, 9
- PIER 6–7, 10
- American Heart Association (AHA), clinical practice guidelines 42
- American Society for Reproductive Medicine (ASRM), varicocele repair 146
- American Urological Association (AUA) guidelines 7–8
 - prostate cancer management 258
 - varicocele repair 146
 - venous thromboembolism prophylaxis 65, **66**
 - patient information 10
 - Symptom Score Index 48
- amitriptyline
 - chronic prostatitis/chronic pelvic pain syndrome 114
 - nocturnal enuresis 396, 397
- amoxicillin **74**, 87
- ampicillin **74**, 87
- ampicillin + gentamicin **74**, 87
- analysis of variance (ANOVA) 22
- androgen deprivation therapy in prostate cancer
 - adjuvant
 - after radical prostatectomy 274–5, 276
 - with radiation therapy 287–9
 - after brachytherapy 289, 290
 - combined androgen blockage 295
 - continuous androgen suppression 295–7
 - intermittent androgen suppression 296–7
 - metastatic disease 293–7, 302
 - timing 293–5
 - neo-adjuvant with radical prostatectomy 262, **263**, 264–5, 267–9
- androgens, prostate cancer 236
- anesthetics, topical in premature ejaculation treatment 127–8
- anterior colporrhaphy 186, **187**, 188, 192
- antibiotic(s)
 - chronic prostatitis 114, 125
 - penile implant coating 141–2
- antibiotics, prophylaxis in urological surgery 50–62
 - clinical implications 55, 56, 59, 61
 - clinical questions 50–1, **52–4**, 55–6, **57–8**, 59, **60**, 61
 - evidence 50–1, **52–4**, 55, 56, **57–8**, 59, **60**
 - forest plot 55, 56, 59, 62
 - literature search 51, 56, 59
 - methods 50–1, **52–4**, 55–6, **57–8**, 59, **60**, 61
 - research implications 61–2
 - risk reduction 59
- antibiotics, UTI prevention/treatment 72
 - class **74**, **76–7**, **81–2**, 86–8
 - duration of therapy **75**, **77–8**, **82–4**, 88–90
 - pediatric 374, **378–81**, 382
 - prophylaxis 72, **74**, **76**, **80**, 85–6, 92
 - route of administration **75**, **79**, **84**, 90–1
- anticholinergic drugs
 - cognitive effects 184
 - side effects 183
 - urinary incontinence in women 182–4
- antiestrogens 149–50
- anti-inflammatory drugs, chronic prostatitis/chronic pelvic pain syndrome 112
- antimicrobial therapy, chronic prostatitis/chronic pelvic pain syndrome 111–12
- antimuscarinic agents
 - efficacy 170–1, **172–3**
 - LUTS associated with BPH 96–7, **98**, 99
 - overactive bladder 96–7, **98**, 99, 170–6
 - safety 175, **176**
 - tolerability 171, **174**, 175
 - urinary incontinence in women 178
- anxiety, premature ejaculation 124
- Appraisal of Guidelines Research and Evaluation (AGREE) Instrument 39, 40
- arginine vasopressin (AVP) 396
- assessing the situation 2
- assigning a domain 2
- augmentin **74**
- authors, conflict of interest 27
- axitinib **344**, 346
- bacille Calmette–Guérin (BCG)
 - bladder cancer immunotherapy 304, 305–6, **307**
 - failure 306–7, **308**
 - interstitial cystitis/painful bladder syndrome 118

Index

- bcl-2, bladder cancer chemotherapy prognostic/predictive marker 327
- Beckwith–Wiedemann syndrome (BWS), Wilms' tumor screening 402
- behavioral interventions
- nocturnal enuresis 394–5, 397, 398
 - pediatric UTIs 387, **388–9**, 390
 - urinary incontinence in women 178–80
- bendroflumethiazide, ureteral stone expulsion 208, **209**, **210**
- benign prostatic hyperplasia (BPH)
- antimuscarinic agents for associated LUTS 96–7, **98**, 99
 - combination medical therapy 94–7, **98**, 99
 - evidence 94–6
 - finasteride effects 96–7, **98**, 99, 239, 240
 - Gyrus bipolar TURP 106–7, **108**
 - laser prostatectomy 104–6, 109
 - literature search 94
 - medical management 94–101
 - monopolar TURP 106–7, **108**
 - open prostatectomy 103–4
 - phytotherapy 99–101
 - saw palmetto therapy 99–101
 - surgical management 103–9
 - transurethral resection in saline 107, **108**, 109
 - TUMT 103–4, 109
 - TUNA 103–4, 109
 - TURP 103–4, 106–7, **108**
- bevacizumab, metastatic renal cell carcinoma 343, 345, 346, 347–8, **349**
- bias 12
- clinical practice guidelines 40–1
 - conflict of interest 27, 41
 - minimizing 19
 - observational studies 34–5
 - protection against 29
 - reporting 34
 - safeguarding against 13–15
 - see also* publication bias
- bibliographic databases 1, 2
- bicalutamide, adjuvant treatment after radical prostatectomy 275
- biofeedback
- pelvic floor in pediatric UTIs 387, **388–9**, 390
 - urinary incontinence in women 180
- bioflavanoids 112
- bisphosphonates, metastatic prostate cancer 298–9, 302
- bladder cancer
- BCG maintenance therapy 305–6, **307**
 - failure 306–7, **308**
 - chemotherapy
 - adjuvant with radical cystectomy 314–15, 319
 - metastatic disease 321, **322**, 323, **324**, 325–7
 - neo-adjuvant 316–17, 319
 - postoperative 304–5, **306–7**
 - prognostic/predictive markers 327 - electromotive mitomycin C 307, **308**
 - fluorescence cystoscopy 309–10
 - metastatic 321–7
 - chemotherapy 321, **322**, 323, **324**, 325–7 - muscle-invasive 314–19
 - progression risk indicators 304
 - radical cystectomy
 - adjuvant chemotherapy 314–15, 319
 - neo-adjuvant chemotherapy 316–17
 - radiotherapy with neo-adjuvant chemotherapy 316–17
 - recurrence rate 316–17
 - superficial 304–12
 - transitional cell carcinoma, BCG-refractory 306–7, **308**
 - TURBT 304–5
 - intravesical instillation of chemotherapeutic agent 304–5, **305–6**
 - second operation 308–9
 - urine markers 310–12
 - urothelial carcinoma 314
 - adjuvant chemotherapy 314–15
 - bladder preservation 317–19 - bladder neck slings 186, **187**
 - bladder neck suspension 186, **187**, 188, 192
 - efficacy in stress incontinence 189–90 - bladder outflow obstruction (BOO), BPH
 - surgical management 103, 105 - bladder preservation in muscle-invasive bladder cancer 317–19
 - blinding 13–14, 19
 - RCTs 20, 21 - BMJ Best Treatments 10
 - BMJ Clinical Evidence 4–5
 - BMJ Point of Care 5–6
 - body mass index (BMI), urinary incontinence in women 179
 - body position change, shock-wave lithotripsy adjuvant therapy 220, **221**
 - Bonferroni correction 15
 - Books@Ovid 8
 - bovine collagen injections 192
 - brachytherapy in prostate cancer 279, 289–90
 - supplemental androgen deprivation 289, 290
 - supplemental external beam radiotherapy 289, 290 - budgets, hospitals 46
 - Burch procedure **187**, 188, 189
 - burden of treatment 30–1
 - buttress operations 186, **187**, 188
- caffeine intake, urinary incontinence in women 179
- calcium channel antagonists, ureteral stone expulsion 201, **202–3**, 215
- shock-wave lithotripsy adjuvant therapy 232–3
- calcium hydroxyapatite 192
- Campbell's Urology* 8
- capital equipment costs 46
- carboplatin
- metastatic bladder cancer 326, 327
 - seminoma 353–4
 - adjuvant treatment 356
- case series, hierarchy of evidence 12
- case-control studies, hierarchy of evidence 12, 13
- ceftibuten **74**, 87
- ceftriaxone **74**, 86–7
- cefuroxime **74**, 87
- cephalexin **74**
- cephazolin **74**, 86
- cephonicid **74**
- Chalmers, Iain 18
- charges 46
- chemotherapy
- nonseminomatous germ cell tumors 360
 - adjuvant for high-risk stage I patients 366, **367–70**, 371
- normal retroperitoneum 364, **365**, 366
 - seminoma 353–4
 - adjuvant therapy 356
- Wilms' tumor 404, 405–6
- chemotherapy in bladder cancer
- adjuvant after radical cystectomy 314–15, 319
 - concomitant with TURBT 318
 - metastatic disease 321, **322**, 323, **324**, 325–7
 - neo-adjuvant
 - after local treatment 316–17
 - prior to radical cystectomy 316–17, 319
 - post TURBT 304–5, **305–6**
 - prognostic/predictive markers 327
- chemotherapy in prostate cancer
- adjuvant after radical prostatectomy 275–6
 - metastatic disease 297–8, 302
 - neo-adjuvant prior to radical prostatectomy 269–71
 - radio-isotope therapy enhancement 299, 302
- children
- nocturnal enuresis 393–9
 - Wilms' tumor 401–6
 - see also* pediatric urinary tract infections
- chiropractic, nocturnal enuresis 398
- chlorthalidone, nocturnal enuresis 397
- chlorthalidone, ureteral stone expulsion 208, **210**
- chromosome 1p, loss of heterozygosity 402–3
- chromosome 16q, loss of heterozygosity 402–3
- chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)
- anti-inflammatory therapy 112
 - antimicrobial therapy 111–12
 - clinical phenotyping 114
 - evidence 112, 113
 - literature search 111, 112
 - UPOINT phenotype classification 114
- ciprofloxacin **74**, 87, 88, 89
- chronic prostatitis/chronic pelvic pain syndrome 113
- cisplatin
- metastatic bladder cancer 321, **322**, 323, **324**, 325–7
 - neo-adjuvant in bladder cancer 316–17
 - radio-isotope therapy enhancement 299, 302
- citalopram, premature ejaculation treatment 125–6
- citation searching 10
- clinical decisions, individualizing 32
- Clinical Evidence 10
- clinical evidence, searching for 3–10
- clinical information 1–2
- Clinical Knowledge Summaries 8
- clinical practice guidelines 38–43
- applicability to specific clinical scenarios 42–3
 - bias sources 40–1
 - development 39–40
 - issues 40–3 - generation process 39–40
 - generation when evidence lacking/poor quality 41–2
 - optimal patient care 38
 - quality 38–9
 - use 40–3

- clinical question
 focused 2–3
 formulation 29–30
 systematic reviews 19–21, 24
- clinical trials 12–16
 analysis elements 14–15
 applying results 15–16
 blinding 13–14, 19
 concealment 13
 confidence interval 14, 15
 data analysis 14
 design elements 13–14
 effect size 15
 equal treatment 14
 expertise-based 14
 follow-up 14
 hierarchy of evidence 12–13
 intention-to-treat 15
 multiple testing 15
 outcome adjudicators 14
 outcomes 15
 patient characteristics 13
 per protocol analysis 15
 point estimate of treatment effect 15
 power calculation 14–15
 prognostic factors 13–14
 randomization 13, 14, 19
 sample size 14–15
 subgroup analyses 15
 underpowered 14–15
- clomiphene
 male infertility 149–53
 pregnancy effects 151, 153
- clomipramine
 nocturnal enuresis 396
 premature ejaculation treatment 125–6, 128
- co-amoxiclav 87
- Cochrane, Archie 18
- Cochrane Central Register of Controlled Trials 8
- Cochrane Collaboration 3–4, 8, 18
 patient information 10
 plain language summaries 10
 Risk of Bias instrument 40
- Cochrane Library 2, 4
 Cochrane Central Register of Controlled Trials 8
- Cochrane Reviews 8
- cognitive behavioral therapy (CBT)
 nocturnal enuresis 394, 396
 premature ejaculation 123–5
- cohort studies, hierarchy of evidence 12, 13
- colporrhaphy, anterior 186
- combined androgen blockage (CAB),
 metastatic prostate cancer 295
- comparison, focused clinical question 2, 3
- complementary therapies, nocturnal enuresis 398
- concealment 13
- confidence interval (CI) 14, 15
 meta-analyses 25
- conflict of interest
 bias 27
 practice guideline development 41
 nonfinancial 41
 systematic reviews 27
- conjugated equine estrogen (CEE) 181
- CONSORT (Consolidated Standards of Reporting Trials) 13, 14
- constipation, pediatric UTIs 387, 390
- continuous androgen suppression (CAS),
 metastatic prostate cancer 295–7, 302
- corticosteroids, ureteral stone
 expulsion 201, 204, 205, 206
- cost(s)
 capital equipment 46
 discounting 46–7
 economic evaluation 47
 health service 47
 nonhealthcare 47
 utilization 46
- cost analyses 45–7
- cost *versus* charge 46
- cost-effectiveness analysis 45, 48
- cost-minimization analysis 48
- cost-to-charge ratios 46
- cost-utility analysis 45, 48
- co-trimoxazole 74, 87, 88
- counseling, nocturnal enuresis 395
- cranberries, UTI prevention/treatment 72, 73, 74, 76, 79, 80, 85, 91–2
 pediatric 387, 389, 390
- cyclophosphamide/cisplatin combination
 in metastatic bladder cancer 321, 322, 323
- cyproterone acetate, metastatic prostate cancer 295
- cystectomy, radical with adjuvant chemotherapy 314–15, 319
- cystitis, interstitial 117–19
- dactinomycin, Wilms' tumor 405
- dapoxetine, premature ejaculation
 treatment 128–9
- DARE (Database of Abstracts of Reviews of Effects) 4, 8
- darifenacin 175, 176
- data extraction, systematic reviews 22
- data synthesis, systematic reviews 22
- decision aids 32
- decision making 32
- deep vein thrombosis (DVT)
 laparoscopic prostatectomy 68
 prevalence 65
 prophylaxis
 duration 69
 open urological surgery 68–9
 optimal method 69
 risk factors 69
- deflacor, ureteral stone expulsion 201, 204, 205
- depression, PDE5 inhibitors 138
- desipramine, nocturnal enuresis 397
- desmopressin, nocturnal enuresis 395–7, 398–9
- detrusor muscle, muscarinic receptors 170
- detrusor overactivity 170
- diabetes, PDE5 inhibitors 137, 138
- Diagnostic and Statistical Manual (DSM) of
 Mental Disorders, premature
 ejaculation definition 120, 121
- diazepam, nocturnal enuresis 397
- diclofenac, nocturnal enuresis 397
- diet, nocturnal enuresis 398
- diethylstilbestrol, metastatic prostate cancer 294
- digital rectal examination (DRE), prostate cancer 237, 238
 low PSA range 245–7
- dimethylsulfoxide (DMSO), interstitial
 cystitis/painful bladder
 syndrome 118
- dipstick analysis, renal trauma 158
- discounting 46–7
- diuretics, ureteral stone expulsion 208, 209–10, 215
- DNA damage to sperm, varicocele
 repair 146
- docetaxel
 metastatic prostate cancer 297–8, 302
 radical prostatectomy
 adjuvant after 276
 neo-adjuvant prior to 270–1
- dose–response gradient 35
- doxazosin 95–6
 chronic prostatitis/chronic pelvic pain
 syndrome 113
 LUTS associated with BPH 96–7, 98, 99
 ureteral stone expulsion 196, 198, 199, 200, 207
- doxorubicin
 intravesical instillation post TURBT 305
 neo-adjuvant prior to radical
 prostatectomy 269, 270
 Wilms' tumor 405
- dry bed training (DBT), nocturnal
 enuresis 394–5, 398
- duloxetine, urinary incontinence in
 women 182
- Durasphere injections 191–2
- dutasteride 95, 96, 236–40
- DynaMed 7
- economic analysis 47–8
- economic evaluation, costs 47
- economic parameters 45–7
 perspective 45–6
- educational interventions
 nocturnal enuresis 394–5
 urinary incontinence in women 178–80
- effect size 15
 magnitude 34
- effectiveness measurement 47–8
- efficacy trials, highly selected study
 population 42
- Egger's regression 26
- ejaculation
 control 122
 delayed 121–2
see also premature ejaculation
- electronic textbooks 8
- EMBASE 10
- E-Medicine 8
- ephedrine, urinary incontinence in
 women 182
- epidermal growth factor receptor (EGFR)
 inhibition 348
- epirubicin, intravesical instillation post
 TURBT 305
- erectile dysfunction 134–42
 alprostadil 138–9
 after radical prostatectomy 140
 definition 134–5
 function recovery after radical
 prostatectomy 139–40
 measurement 135
 PDE5 inhibitors
 after radical prostatectomy 140
 effectiveness 135, 136–7, 137–8
 safety 135, 136–7, 137–8
 penile implants 141–2
 premature ejaculation 125
 prostaglandin E1 138–40
 search strategy 135

Index

- erectile dysfunction (*cont.*)
 vacuum erection devices after radical prostatectomy 140
- erlotinib 346, 348
- estramustine
 metastatic prostate cancer 297, 298
 neo-adjuvant prior to radical prostatectomy 269, 270, 271
- estrogens, stress urinary incontinence in women 181, 182
- European Association of Urology (EAU) guidelines 40
- European Randomized Study of Screening for Prostate Cancer (ERSPC) 243
 incidence of prostate cancer 248
 PSA in early detection 244, 245–6
 screening impact on mortality 251–2
- everolimus 344
 metastatic renal cell carcinoma 346
- evidence
 clinical question type 42
 grading systems 39
 indirectness 33–4
 insufficient 41–2
 see also quality of evidence
- evidence tables 22, 24
- evidence-based medicine, historical aspects 18–19
- EvidenceUpdates + 5, 8
- expert opinion 42
 hierarchy of evidence 12
- external beam radiotherapy for prostate cancer 279
 adjuvant androgen deprivation therapy 287, 288, 289
 after brachytherapy 289–90
 dose-escalated 283
 optimal dose 279, 280–2, 283–4
 radio-isotope adjunct 299, 302
- false-positive results, multiple outcome analysis 15
- faradization, nocturnal enuresis 398
- fesoterodine 171, 172, 175
 adverse events 175, 176
 tolerability 174
- filtered sources of information 1
- finasteride 94, 95, 96, 236–40, 241
 benign prostatic hyperplasia symptom treatment 96–7, 98, 99, 239, 240
 biopsy detection of prostate cancer 238–9
 cancer detection increase 239
 chronic prostatitis/chronic pelvic pain syndrome 113
 digital rectal examination sensitivity 238
 LUTS associated with BPH 96–7, 98, 99, 239, 240
 prostate volume decrease 239
 PSA sensitivity 238, 240
 sexual function effects 239
 side effects 239
 survival advantage 48
- fixed effects model 25
- fluid restriction, urinary incontinence in women 179
- fluorescence cystoscopy, bladder cancer recurrence rates 309–10
- fluoxetine, premature ejaculation treatment 125–6, 128
- flutamide
 adjuvant treatment after radical prostatectomy 275
 metastatic prostate cancer 295
- follicle-stimulating hormone (FSH), stimulation by clomiphene 151–2
- follow-up 14
- forest plots 26
- fosfomycin 74, 87
- FreeBooks4-Doctors 8
- full-spectrum home training (FSHT) 394–5, 398
- funnel plot 26
- gatifloxacin 88–9
- gemcitabine in metastatic bladder cancer
 cisplatin combination 325
 paclitaxel combination 325–6
- genitourinary trauma 156–9
- gentamicin 89
- germ cell tumors 351
 see also nonseminomatous germ cell tumors; seminoma
- glomerular filtration rate, nephrectomy outcome 339, 340
- glutathione, bladder cancer chemotherapy prognostic/predictive marker 327
- gonadotrophin-releasing hormone (GnRH), stimulation by clomiphene 151–2
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system 30, 32–3, 39
- antibiotic prophylaxis in urological surgery 50, 52, 60
- antimuscarinic agents for LUTS associated with BPH 96–7, 98, 99
- desirable/undesirable effects 36
- nephrectomy after abdominal trauma 159
- quality of evidence 42–3
- recommendations 30, 31
- strength of evidence 34
 differences 35
- venous thromboembolism in urological surgery 66
- graduated compression stockings (GCS) 66, 68
- Gyrus bipolar TURP 106–7, 108
- hammock hypothesis of stress urinary incontinence 186
- hand-assisted laparoscopic nephrectomy (HALN) 329
- handbooks 8
- health economics 45–8
 cost *versus* charge 46
 perspective 45–6
- health service costs 47
- hematuria, blunt abdominal trauma evaluation 156–8
- hemihypertrophy, Wilms' tumor screening 402
- heparin 67, 68, 69
- Her/neu, bladder cancer chemotherapy prognostic/predictive marker 327
- hierarchy of evidence 12–13, 20–1
- holmium laser enucleation of the prostate (HoLEP) 104–6, 109
- homeopathy, nocturnal enuresis 398
- hormone replacement therapy, stress urinary incontinence in women 181
- hospitals, budgets 46
- hydrochlorothiazide, ureteral stone expulsion 208, 209
- 8-hydroxy-2-deoxy-guanosine (8-OHdG) 146
- 4-hydroxy-2-nonenal (4-HNE) 146
- hyperthyroidism, premature ejaculation 125
- hypnosis, nocturnal enuresis 398
- iliac lymph node irradiation, seminoma 355
- imipramine
 nocturnal enuresis 394, 396, 397, 398, 399
 urinary incontinence in women 181–2
- incontinence procedures
 VTE prophylaxis 67–8
 see also urinary incontinence in women
- indapamide, ureteral stone expulsion 208, 210, 211, 212
- indometacin, nocturnal enuresis 397–8
- industry funding 41
- Institute of Medicine 41
- insurance companies 46
- integral theory of stress urinary incontinence 186
- intensity-modulated radiation therapy (IMRT) 279, 284, 285–6, 287
- intention-to-treat 15
 RCTs 21
- interferon alpha (IFN-alpha), metastatic renal cell carcinoma 343, 347–8, 349
- interleukin 2 (IL-2)
 high-dose therapy 344–5, 349
 metastatic renal cell carcinoma 343, 344–5, 346, 349
- intermittent androgen suppression (IAS), metastatic prostate cancer 296–7, 302
- intermittent pneumatic compression (IPC) devices 66, 68
- International Index of Erectile Dysfunction (IIEF) 135
- interpersonal difficulty, premature ejaculation 122–3
- interstitial cystitis/painful bladder syndrome 117–19
- intervention
 causality 21
 effectiveness 16
 efficacy 16
 focused clinical question 2, 3, 9
- intervention settings, systematic reviews 20
- interventions of interest, systematic reviews 19–20
- intracavernous injection of vasoactive drugs
 erectile dysfunction 138, 139
 erectile function recovery after radical prostatectomy 140
 premature ejaculation treatment 128
- intracytoplasmic sperm injection (ICSI), varicocele 146
- intraurethral delivery 138–9
 erectile function recovery after radical prostatectomy 140
- intravaginal ejaculatory latency time (IELT) 120, 121, 122
 cut-off for premature ejaculation 123
- intravenous pyelography, renal trauma 157, 158
- ixabepilone, metastatic bladder cancer 326
- ketoconazole, neo-adjuvant prior to radical prostatectomy 269, 270
- kidney cancer
 localized 329–41
 metastatic 343–9
 Wilms' tumor 401–6

- laparoscopy, urological
 VTE prophylaxis 68–9
see also named laparoscopic procedures
- laser prostatectomy 104–6, 109
- leuprorelin, adjuvant after radical prostatectomy 276
- levator ani muscle, reflex contraction 186
- levofloxacin 89
- lidocaine, premature ejaculation
 treatment 127–8
- lifestyle interventions, urinary incontinence
 in women 178–80
- literature review 2
- literature searches
 scoring system 147, **148**
 systematic reviews 21, 24
- lithotripsy 218–19
- loss of heterozygosity (LOH) 402–3
- low molecular weight heparin (LMWH) 67
 DVT prophylaxis 69
 VTE prophylaxis 68
- low-dose unfractionated heparin
 (LDUH) 67, 68, 69
- lower urinary tract symptoms (LUTS) 94
 antimuscarinic agents for symptoms
 associated with BPH 96–7, **98**, 99
- luteinizing hormone (LH), stimulation by
 clomiphene 151–2
- lymph node dissection
 renal cell carcinoma 333, **334**, 335–7
 complications **334**, 336
 survival in **334**, 335–6
*see also retroperitoneal lymph node
 dissection*
- lymph nodes, radiotherapy following
 orchidectomy for seminoma 355–6
- lymphadenectomy *see* lymph node
 dissection
- Macroplastique injections 191–2
- male infertility 146–53
 clomiphene citrate 149–53
 varicocelelectomy 146–7, **148**, 149
- Markov model 48
- Marshall–Marchetti–Krantz procedure
187, 188
- MD Consult 8
- medical expulsive therapy (MET) 195, 225
 acetohydroxamic acid 195, 213–15
 alkali citrate therapy 195, 211, 213, 215
 allopurinol 195, 208, 211, **212**
 alpha-adrenergic antagonists 195–6,
197–200, 201, 215
 calcium channel antagonists 201, **202–3**,
 215
 corticosteroids 201, **204**, 205
 diuretics 208, **209–10**, 215
 following shock-wave lithotripsy 231–3
 shock-wave lithotripsy 205, **206–7**,
 208, 215
- medical science advancement 41
- Medicare 46
- Medline 9, 10
- MedlinePlus 10
- medroxyprogesterone acetate, stress urinary
 incontinence in women 181
- MeSH subject headings 9, 10
- meta-analyses 18–19, 22–3, 24–6
 categorical data 24–5
 combining studies with different
 designs 26
 confidence intervals 25
 continuous data 24, 25
- forest plots 26
- heterogeneity of studies 23, 25–6
 unexplained 33
- pooling of data 22–3, 25
- statistical models 25
- statistical significance 23
- statistics 24–5
- variables 24, 25
- metalloproteinase, bladder cancer
 chemotherapy prognostic/predictive
 marker 327
- meta-regression 23
- metastases
 bladder cancer 321–7
 kidney cancer 343–9
 lymph node 333, 337
 prostate cancer 293–302
 seminoma 351
 VEGF role 337
- methotrexate in metastatic bladder cancer
 cisplatin combination 321, **322**, 323, **324**,
 325, 326, 327
 single agent 326
 vinblastine combination 323, **324**, 325,
 326, 327
- methylprednisolone, ureteral stone
 expulsion 201, **204**, 205
- microhematuria, renal trauma 157, 158
- microscopic urinalysis, renal trauma 158
- mid-urethral sling 186, **187**, 190–1, 192, 193
- mitomycin C
 electromotive in bladder cancer 307, **308**
 intravesical instillation post TURBT 305
- mitoxantrone
 adjuvant after radical prostatectomy 276
 metastatic prostate cancer **297**, 298
- monopolar TURP (MTURP) 106–7, **108**
- morbidity 46
- m-TOR inhibitors, metastatic renal cell
 carcinoma 348–9
- m-TOR pathway inhibition 343, **344**
- multiple testing 15
- muscarinic receptors, detrusor muscle 170
- MUSE™ 138–9
- naftopidil 97, **98**
- narrative synopsis 19
- National Guideline Clearinghouse
 (NGCH) 8, 38, 40
 conflict of interest survey 41
- National Library of Medicine (Bethesda,
 MD) 10
- NCBI Bookshelf 8
- nephrectomy
 cytoreductive 337
 metastatic renal cell carcinoma 343–4
 debulking 343–4
 partial for Wilms' tumor 406
 predictors after abdominal trauma 158–9
- nephrectomy, partial
 complications 340
 laparoscopic 339
 renal cell carcinoma 337–41
 renal function outcome 339–40
- nephrectomy, radical 329–30
 laparoscopic 329–30
 renal cell carcinoma 330, **331**, 332–3,
 339
 open 329
 renal cell carcinoma 330, **331**, 332–3
 partial nephrectomy comparison 338–41
 renal function outcome 339–40
- nephroblastoma *see* Wilms' tumor
- nephrolithiasis 218, 219
- neurogenic bladder, pediatric UTIs 390
- new technologies, economics 46
- nifedipine, ureteral stone expulsion **198**,
200, 201, **202–4**, **206**
 shock-wave lithotripsy adjuvant
 therapy 232–3
- nilitamide, metastatic prostate cancer 295
- nitrofurantoin 74, 87
 prophylactic in pediatric UTIs 382,
383–6, 387
- nocturnal enuresis 393–9
 alarms 394, 395–6, 397, 398–9
 behavioral interventions 394–5, 396,
 397, 398
 complementary therapies 398
 desmopressin 395–7, 398–9
 educational interventions 394–5
 monosymptomatic 393
 polysymptomatic 393
 psychological interventions 396, 398
 tricyclic antidepressants 394, 396, 397,
 398–9
- nonseminomatous germ cell tumors 351,
 358–71
 chemotherapy 360
 adjuvant for high-risk stage I
 patients 366, **367–70**, 371
 normal retroperitoneum after 364,
365, 366
 high-risk stage I patient
 management 366, **367–70**, 371
 orchidectomy 358
 retroperitoneal lymph node dissection
 360, **361–3**, 364, 366, **367–70**, 371
 scrotal violation 358, **359**, 360
- norepinephrine reuptake inhibitors (NRIs),
 urinary incontinence in women 182
- norfloxacin 74, 87, 88
- nortriptyline, chronic prostatitis/chronic
 pelvic pain syndrome 114
- obesity, urinary incontinence in
 women 179
- observational studies 13
 bias 34–5
 generalizability 21
 hierarchy of evidence 20, 21
 placebo controls 21
 quality of evidence 35
 strength of evidence 34
 study quality assessment 24
- odds ratio (OR) 14
- orchidectomy
 metastatic prostate cancer 294, 302
 nonseminomatous germ cell tumors 358
 seminoma 351, 356
 lymph node radiotherapy 355
- outcome
 effectiveness measurement 47–8
 failure to report 34
 focused clinical question 2, 3, 9
 recommendation strength 35
 importance in 32
 strength of evidence differences 35
- outcome adjudicators 14
- outcomes of interest, systematic reviews 20
- overactive bladder syndrome
 anticholinergic drugs 183
 antimuscarinic agents 96–7, **98**, 99, 170–6
 urinary incontinence in women 179
- overgrowth syndromes 402
- OVID 10

Index

- oxidative stress, varicocele repair 146
oxybutinin 171, 172
 adverse events 175, 176
 interstitial cystitis/painful bladder syndrome 118
 nocturnal enuresis 397
 tolerability 174, 175
 urinary incontinence in women 183
- p53, bladder cancer chemotherapy prognostic/predictive marker 327
- paclitaxel, gemcitabine combination in metastatic bladder cancer 325–6
- papaverine, premature ejaculation treatment 128
- paroxetine, premature ejaculation treatment 125–6, 128
- patients
 characteristics 13
 information for 10
- pazopanib 344, 346
- pediatric urinary tract infections 373–90
 antibiotic treatment
 duration 374, 378–81, 382
 prophylactic 382, 383–6, 387
 cranberries 387, 389, 390
 diagnosis 374
 pelvic floor biofeedback 387, 388–9, 390
 prevention 387, 388–9, 390
 urine collection methods 373–4, 375–7
- pelvic floor muscle therapy (PFMT)
 with biofeedback 180
 urinary incontinence in women 178, 179–80
- pelvic lymph node irradiation 279, 284, 285, 287
 seminoma 355
- pelvic organ prolapse 187, 188
- pelvic pain syndrome treatment 111–15
- pelvic reconstruction, VTE prophylaxis 67–8
- penile implants
 antibiotic coating 141–2
 erectile dysfunction 141–2
 infection complications 141
- pentosan polysulfate 112
 interstitial cystitis/painful bladder syndrome 117–18
- per protocol analysis 15
- percussion, diuresis and inversion (PDI) therapy 220, 221
- percutaneous nephrolithotomy (PCNL) 218–19
- Perlman syndrome 402
- personal distress, premature ejaculation 122–3
- perspective
 hospital 45–6
 patient 45
- p-glycoprotein, bladder cancer chemotherapy prognostic/predictive marker 327
- phentolamine, premature ejaculation treatment 128
- phenylpropanolamine, urinary incontinence in women 182
- phosphodiesterase type 5 enzyme (PDE5)
 inhibitors 134
 contraindications 138
 effectiveness 135, 136–7, 137–8
 efficacy 137–8
- erectile function recovery after radical prostatectomy 140
 mechanism of action 137
 premature ejaculation 125
 safety 135, 136–7, 137–8
- Phyllanthus niruri*, shock-wave lithotripsy adjuvant therapy 220, 221
- phytotherapy, BPH therapy 99–101
 PICOTS 2, 3, 9
 applicability threats 42–3
- pipemidic acid 74, 87
- placebo controls, RCTs 20, 21
- platelet-derived growth factor (PDGF) inhibition 346
 metastatic renal cell carcinoma 345, 346
- platinum chemotherapy, nonseminomatous germ cell tumors with normal retroperitoneum 364, 365, 366
- point estimate of treatment effect 15
- point-of-care resources 4–7
- pooling studies/data, meta-analyses 22–3, 25
- population, focused clinical question 2, 3, 9
- Population, Intervention, Comparator, Outcome, Timing, and Setting
 see PICOTS
- population of interest, systematic reviews 19
- porcine dermal implant 192
- potassium citrate 195
 ureteral stone expulsion 211, 213
- potassium–magnesium citrate, ureteral stone expulsion 211, 213
- potassium–titanyl–phosphate (KTP) laser prostatectomy 104, 106, 109
- power calculation 14–15
- practice guidelines 7–8
- preappraised sources 8–9
- pregabalin, chronic prostatitis/chronic pelvic pain syndrome 114
- pregnancy
 clomiphene effects 151, 153
 tamoxifen effects 151
 varicolectomy effects 147, 149, 152
- premature ejaculation
 acquired 123, 125
 alpha-1-adrenergic antagonists 126–7
 anxiety 124
 cognitive behavioral therapy 123–5
 erectile dysfunction 125
 evidence for treatment 120–3
 hyperthyroidism 125
 intracavernous injection of vasoactive drugs 128
 lifelong 123
 negative personal consequences 122–3, 128–9
 phosphodiesterase inhibitors, type V 125
 psychosexual therapy 123–5
 safety of pharmacotherapy 125–8
 SSRIs 124–5, 125–6, 128–9
 topical anesthetics 127–8
 tramadol 127
 treatment 120–9
- priapism, alprostadil side effect 139
- prilocaine, premature ejaculation treatment 127–8
- primary anastomotic urethroplasty (PAU), bulbar urethral strictures 164, 166–8
- prognosis, cohort studies 13
- prognostic factors 13–14
- propiverine hydrochloride 97, 98, 171, 172, 173, 174, 175
- prostaglandin E1, erectile dysfunction 138–40
- prostate cancer
 adjuvant radiation therapy 271–4
 androgen deprivation therapy
 adjuvant after radical prostatectomy 274–5, 276
 adjuvant with radiation therapy for prostate cancer 287–9
 after brachytherapy 289, 290
 continuous androgen suppression 295–7
 intermittent androgen suppression 296–7
 metastatic disease 293–7, 302
 neo-adjuvant with radical prostatectomy 262, 263, 264–5, 267–9
 biopsy detection 238–9, 240
 brachytherapy 279, 289–90
 chemoprevention 236–41
 detection
 biopsy 238–9, 240
 early with screening 248, 249–50, 251
 increase with finasteride 238–9, 240
 digital rectal examination 237, 238
 early detection 243–52
 expectant management compared with radical prostatectomy 255–9
 finasteride
 enhancement of biopsy detection 238–9, 240
 survival advantage 48
 incidence 236
 screened/nonscreened population 247–8
 locally advanced disease 267–77
 management controversies 255
 management strategies 255–9
 meta-analyses 258
 metastatic 293–302
 androgen suppression therapy 293–7, 302
 bisphosphonates 298–9, 302
 chemotherapy 297–8
 palliative treatment 293
 radio-isotopes in pain alleviation 299, 300–1, 302
 morbidity 236
 mortality 236
 screening impact 251–2
 pathology 237–8
 pelvic lymph node irradiation 279, 284, 285, 287
 population-based observational studies 257–8
- PSA
 early detection 243–5, 245–7
 finasteride impact on sensitivity 238, 240
 radiation therapy 279–90
 adjuvant 271–4
 adjuvant androgen deprivation 287–9
 randomized controlled trials 256–7, 258, 259
 risk 236
 categories 279
 screening 243–52
 early detection 248, 249–50, 251
 mortality impact 251–2
 selenium in chemoprevention 240–1

- surgical management
 - clinically localized disease 255–65
 - compared to watchful waiting 255–9
 - locally advanced disease 267–77
- treatment failure risk 267
- vitamin E in chemoprevention 240–1
- watchful waiting 255–9
- see also* prostatectomy
- Prostate Cancer Prevention Trial (PCPT) 237–40, 241
- PSA in early detection 244
- Prostate Intervention Versus Observation Trial (PIVOT) 259
- Prostate Testing for Cancer and Treatment (PROTECT) trial 259
- prostatectomy
 - laparoscopic 68
 - laser 104–6, 109
 - open for BPH management 103
 - radical, with pelvic lymphadenectomy 68
- prostatectomy, radical
 - adjuvant therapy after
 - chemotherapy 275–6
 - hormonal 274–5, 276
 - radiotherapy 271–4
 - androgen deprivation therapy
 - adjuvant 274–5, 276
 - neo-adjuvant 262, 263, 264–5, 267–9
 - chemotherapy
 - adjuvant 275–6
 - neo-adjuvant 269–71
 - compared with expectant management 255–9
 - hospital volume effects 259, 260, 261–2
 - length of stay 259, 260, 261–2
 - neo-adjuvant treatment
 - androgen deprivation therapy 262, 263, 264–5, 267–9
 - chemotherapy 269–71
 - outcomes 259, 260, 261–2
 - PDE5 inhibitors 137, 138
 - with pelvic lymphadenectomy 68
 - surgeon volume effects 261, 262
 - volume–outcome relationship 259, 260, 261–2
- prostate-specific antigen (PSA)
 - adjuvant radiotherapy after radical prostatectomy 273, 274
 - early detection of prostate cancer 243–5
 - low range and additional investigations 245–7
 - finasteride impact on sensitivity 238, 240
- prostate-specific therapy, chronic prostatitis/chronic pelvic pain syndrome 112–14
- prostatitis treatment 111–15
 - premature ejaculation improvement 125
- pseudoephedrine, urinary incontinence in women 182
- psychological interventions, nocturnal enuresis 396, 398
- psychosexual therapy, premature ejaculation 123–5
- publication bias
 - conflict of interest 41
 - quality of evidence 34
 - systematic reviews 26
- PubMed 8, 9
- pubococcygeus muscle 186
- pubourethral ligaments 186
- pubovaginal sling 186, 187, 190, 192–3
- pulmonary embolism (PE) 65
 - laparoscopic prostatectomy 68
- quality of evidence 29–36, 34
 - bias 34
 - direction 34–5
 - dose–response gradient 35
 - evaluating 30
 - factors decreasing 33–4
 - factors increasing 34–5
 - imprecision 34
 - inconsistent results 33
 - indirectness of evidence 33–4
 - methodological 32–5
 - methodology limitations 33
 - publication bias 34
 - recommendations 30–6
 - strength of evidence differences 35
 - unexplained heterogeneity of results 33
- quality of life 46
 - questionnaires 47–8
- quality-adjusted life years (QALYs) 48
- quercetin 112
- radiation therapy
 - bladder cancer
 - concomitant with TURBT 318
 - neo-adjuvant chemotherapy 316–17
 - para-aortic plus ipsilateral iliac and pelvic nodal 355
 - prostate cancer 279–90
 - adjuvant after radical prostatectomy 271–4
 - adjuvant androgen deprivation therapy 287–9
 - retroperitoneal para-aortic 355
 - seminoma
 - adjuvant 354–5
 - late toxicity 352–3
 - see also* brachytherapy in prostate cancer
- radical prostatectomy *see* prostatectomy, radical
- radio-isotopes, metastatic prostate cancer
 - pain alleviation 299, 300–1, 302
- Radiotherapy and Androgen Deprivation in Combination after Local Surgery (RADICALS) 273
- random effects model 25
- randomization 13, 14, 19
 - RCTs 20, 21
 - remote 13
- randomized controlled trial (RCT) 3, 9
 - allocation concealment 33
 - analysis elements 14–15
 - blinding 20, 21
 - design elements 13–14
 - dropout rates 21
 - efficacy measurement 20, 42
 - expertize-based 12–13
 - hierarchy of evidence 12–13, 20–1
 - highly selected study population 42
 - historical aspects 19
 - intention-to-treat 21
 - placebo controls 20, 21
 - quality of evidence 33
 - randomization 20, 21
 - Risk of Bias instrument 40
 - study quality 21
 - assessment 24
 - weaknesses 20–1
- receptor tyrosine kinases (RTKs), inhibition 345–6
- recommendations
 - desirable effects 30, 31
 - GRADE system 30, 31
 - interpreting 35–6
 - making 30
 - methodology limitations 33
 - observational studies 34
 - outcome importance 32
 - strength 30–1, 35
 - methodological quality of evidence 32–5
 - strong 30, 31
 - interpreting 31–2
 - undesirable effects 30–1
 - weak 30, 31
 - interpreting 31–2
- 5-alpha-reductase inhibitors 94, 236
- chronic prostatitis/chronic pelvic pain syndrome 112–14
- Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial 237
- renal cell carcinoma (RCC) 329–41
 - clear cell histological variant 345
 - immunotherapy 343, 344–5, 346
 - laparoscopic nephrectomy 330, 331, 332–3
 - lymph node dissection 333, 334, 335–7
 - metastatic 343–9
 - IL-2 immunotherapy 343, 344–5, 346
 - m-TOR inhibitors 348–9
 - receptor tyrosine kinase inhibitors 345–8
 - treatment options 345–8, 349
 - partial nephrectomy 337–41
 - risk factor stratification scale 343
 - renal injury, blunt abdominal trauma 156–8
- renal stone disease
 - adjuvant therapy following surgery 219–20, 221
 - medical management 195–215
 - shock-wave lithotripsy 218–22, 223
 - adjuvant therapy following surgery 219–20, 221
 - small asymptomatic calyceal stones 220–2
 - stone-free rate 218–19
 - surgical management 218–22, 223
- reporting bias 34
- reports, hierarchy of evidence 12
- research funding, conflict of interest 41
- resiniferatoxin, interstitial cystitis/painful bladder syndrome 118
- resource consumption 30
- retroperitoneal lymph node dissection
 - laparoscopic for nonseminomatous germ cell tumors 360, 361–3, 364
 - nonseminomatous germ cell tumors 360, 361–3, 364, 366, 367–70, 371
 - high-risk stage I patients 366, 367–70, 371
 - platinum-based chemotherapy for nonseminomatous germ cell tumors 364, 365, 366
- retropubic bladder neck suspension 186, 187, 188, 192
 - efficacy in stress incontinence 189–90
- RevMan 50
- Risk of Bias instrument 40
- ritual shaming, nocturnal enuresis 396
- rofecoxib 112

Index

- Sackett, David 18
samarium-153, metastatic prostate cancer 299, **300–1**
sample size 14–15
meta-analysis 23
saw palmetto, BPH therapy 99–101
Scopus 10
scrotal violation, nonseminomatous germ cell tumors 358, **359**, 360
selected sources of information 1
selective serotonin reuptake inhibitors (SSRIs)
adverse effects 126
premature ejaculation treatment 124–6, 128–9
urinary incontinence in women 182
selenium, prostate cancer prevention 240–1
Selenium and Vitamin E Cancer Prevention Trial (SELECT) 240–1
semen
clomiphene citrate effects 153
varicocele effects 147, 149
seminoma 351–6
adjuvant treatment 354–6
late toxicity 352–4
chemotherapy 353–4
adjuvant 356
co-existing illnesses 352
lymph node involvement 351
management plan 351–4
metastases 351
orchidectomy 351, 356
lymph node radiotherapy 355
prognostic factors 352, 354
radiation therapy 352–3
adjuvant 354–5, 356
lymph nodes 355
relapse
prognostic factors 352, **353**
rate 354–6
stage 1 351–6
treatment options 351
sepsis prevention 50–1, **52–4**, 55–6, **57–8**, 59, **60**, 61–2
Serenoa repens (saw palmetto) 99–101
sertraline, premature ejaculation treatment 125–6, 128
sexual dysfunction, finasteride effects 239
sexual intercourse, prolonged 121–2
sexual satisfaction, premature ejaculation 122
shock, renal trauma 157, 158
shock-wave lithotripsy (SWL) 218–19
adjuvant therapy 219–20, **221**, 232–3
antibiotic prophylaxis in urological surgery 51, **53–4**, 55
medical expulsive therapy following 231–3
percussion, diuresis and inversion therapy 220, **221**
Phyllanthus niruri adjuvant therapy 220, **221**
renal stones 218–22, **223**
shock-wave delivery rate effect 222, **223**, 233
small asymptomatic renal calyceal stones 220–2
tamsulosin adjuvant therapy 219–20, **221**, 232–3
ureteral stent placement 230–1
ureteral stone disease 225–8, 230–4
ureteral stones 225
expulsion 205, **206–7**, 208, 215, 231–3
side effects, common minor 30
sildenafil
effectiveness 135, **136–7**, 137, 138
erectile function recovery after radical prostatectomy 140
safety 135, **136–7**, 137, 138
Simpson–Golabi–Behmel syndrome 402
society, perspective 46
sodium–potassium citrate, ureteral stone expulsion 211, 213
solifenacin 171, **173**, 175
sorafenib, metastatic renal cell carcinoma 343, 345, 346, 347, 348, **349**
SPARC mid-urethral sling 191, 192
sperm
DNA damage and varicocele repair 146
varicolectomy 149, 150, 151, 152
spinal cord injury, PDE5 inhibitors 137, 138
Spitzer, Walter O. 18
sponsors, outcomes favorable to 41
Standard Treatment Against Restricted Treatment (START) trial 259
statistical power 23
statistical significance 23
StatRef 7, 8
stone-free rate (SFR), renal stone disease 218–19
strontium-89, metastatic prostate cancer 299, **300–1**
subgroup analyses 15
sulfisoxazole **74**
sunitinib
metastatic bladder cancer 326
metastatic renal cell carcinoma 343, 345, 346, 347, 348, **349**
suprapubic aspiration, pediatric urine collection 373, 374
survival, effectiveness measurement 47
synthesized sources of information 1–2, 3–8, 9
systematic reviews 3–4, 9, 18–27
clinical question 19–21
combining studies with different designs 26
conducting 19–23
conflict of interest 27
in production 41
data extraction/synthesis 22
evaluating 23–7
evidence tables 22, 24
exclusion criteria 19, 20, 21
inclusion criteria 19, 20, 21
interpretation 26–7
intervention settings 20
interventions of interest 19–20
literature searches 21, 24
outcomes of interest 20
population of interest 19
publication bias 26
questions 24
statistical models 25
steps in performing 19–23
study design 20
study quality 21
assessment 24
transparency of procedures 24
tadalafil **136–7**, 137, 138
tamoxifen, pregnancy effects 151
tamsulosin 95, 96
chronic prostatitis/chronic pelvic pain syndrome 113
LUTS associated with BPH 96–7, **98**, 99
saw palmetto trial for BPH 100
shock-wave lithotripsy adjuvant therapy 219–20, **221**, 232–3
ureteral stone expulsion 196, **197–200**, 201, **204**, 205, **206–7**, 215
shock-wave lithotripsy adjuvant therapy 232–3
tanoxicam, ureteral stone expulsion 233
temsirolimus, metastatic renal cell carcinoma 343, 346, 348–9
tension-free vaginal tape (TVT) **189**, 190–1, 192
terazosin 95, 97, **98**
chronic prostatitis/chronic pelvic pain syndrome 113
premature ejaculation treatment 127
ureteral stone expulsion 196, **198**, **199**, **200**
testicular cancer 358–71
see also seminoma
testosterone 236
textbooks 8
thiazide diuretics, ureteral stone expulsion 208, **209–10**, 215
three-dimensional conformal radiotherapy (3D-CRT) 279, 283–4, **285–6**, 287
thromboprophylaxis 65
lymphocele formation 68
tolterodine 97, **98**, 99, 171, **173**, 175
toxicity endpoints 35
tramadol, premature ejaculation treatment 127
transrectal biopsy of the prostate, antibiotic prophylaxis in urological surgery 55–6, **57–8**, 59, **60**
transrectal ultrasound (TRUS) in prostate cancer, low PSA range 245–7
transurethral endoscopic procedures, VTE prophylaxis 67
transurethral microwave therapy (TUMT) 103–4, 109
transurethral needle ablation (TUNA) 103–4, 109
transurethral resection of bladder tumor (TURBT) 304–5
bladder preservation 318–19
concomitant chemotherapy and radiotherapy 318
fluorescence cystoscopy 310
intravesical instillation of chemotherapeutic agent 304–5, **305–6**
second operation 308–9
white light cystoscopy 310
transurethral resection of the prostate (TURP) antibiotic prophylaxis in urological surgery 59, 61, 62
BPH treatment 103–4
Gyrus bipolar 106–7, **108**
laser prostatectomy comparison 104–6
VTE prophylaxis 67
transurethral resection in saline (TURIS) 107, **108**, 109
transvaginal needle suspension 186, **187**, 188–9, 192
trastuzumab, metastatic bladder cancer 326
trauma, genitourinary 156–9
trichloromethiazide, ureteral stone expulsion 208, **210**

- tricyclic antidepressants, nocturnal enuresis 394, 396, 397, 398–9
- trimethoprim 74, 87
- trimethoprim–sulfamethoxazole 74
- prophylactic in pediatric UTIs 382, 383–6, 387
- TRIP (Turning Research Into Practice) 8
- tropium, adverse events 175
- t-tests 22
- type of study, focused clinical question 2, 3, 9
- UK Health Technology Assessment programme 40
- unfiltered sources of information 1
- filtering unfiltered databases 9–10
- UPOINT phenotype classification, chronic prostatitis/chronic pelvic pain syndrome 114
- urease inhibitors 195
- ureteral stent placement
- after ureteroscopy 228, 229, 230
- with shock-wave lithotripsy 230–1
- ureteral stone disease
- distal 225–8
- medical management 195–215
- middle 225–8
- proximal 225–8
- shock-wave lithotripsy 225–8, 230–4
- surgical management 225–34
- ureteroscopy 225–30, 234
- ureteral stone expulsion 195
- acetohydroxamic acid 213–15
- alkali citrate therapy 211, 213, 215
- allopurinol 208, 211, 212
- alpha-adrenergic antagonists 195–6, 197–200, 201, 215
- calcium channel antagonists 201, 202–3, 215
- corticosteroids 201, 204, 205
- diuretics 208, 209–10, 215
- shock-wave lithotripsy 205, 206–7, 208, 215
- following 231–3
- tamsulosin 215
- ureteroscopy (URS) 218–19
- antibiotic prophylaxis in urological surgery 50–1, 52
- ureteral stent placement 228, 229, 230
- ureteral stones 225–30, 234
- urethral bulking 186, 187, 192
- efficacy 191–2
- urethral catheterization, pediatric urine collection 373, 374
- urethral stricture disease 161–8, 162–3, 164
- buccal mucosa graft 164, 165
- bulbar 164, 165
- optimal treatment 164, 166–8
- early endoscopic realignment 161–2, 162–3, 164
- etiology 161
- evidence 161–2, 162–3, 164
- literature search 161
- penile 164, 165
- suprapubic cystostomy and delayed treatment 161–2, 162–3, 164
- treatment 161
- urethropelvic ligaments 186
- urethroplasty, primary anastomotic (PAU), bulbar urethral strictures 164, 166–8
- urethrotomy, vision internal (VIU), bulbar urethral strictures 164, 166–8
- urinary incontinence in women
- anterior colporrhaphy 186, 187, 188, 192
- anterior vaginal repair 187–8
- anticholinergic drugs 182–4
- behavioral modification 178–80
- bladder neck suspension 186, 187, 188, 189–90, 192
- buttress operations 186, 187, 188
- education 178–80
- lifestyle modification 178–80
- medical management 178–84
- mid-urethral sling 186, 187, 190–1, 192, 193
- mixed 179, 180, 181
- pharmacological treatment 180–2
- pubovaginal sling 186, 187, 190, 192–3
- stress 179, 180–2, 186–93
- patient populations 187–8
- surgical treatment 186–93
- tension-free vaginal tape 189, 190–1, 192
- transvaginal needle suspension 186, 187, 188–9, 192
- urethral bulking 192
- urge 179, 180, 181
- urinary pH alkalinization, interstitial cystitis/painful bladder syndrome 118
- urinary tract infection 72–92
- antibiotic treatment
- class 74, 76–7, 81–2, 86–8, 92
- duration 75, 77–8, 82–4, 88–90, 92
- prophylactic 72, 74, 76, 80, 85–6, 92
- route of administration 75, 79, 84, 90–1, 92
- cranberries in prevention/treatment 72, 73, 74, 76, 79, 80, 85, 91–2
- evidence 73
- grade profile 73, 79, 80
- management 72
- pediatric 373–90
- systematic literature review 72–3
- urine collection, pediatric methods 373–4, 375–7
- urine markers, bladder cancer 310–12
- urogenital diaphragm, reflex contraction 186
- urological surgery *see* antibiotics, prophylaxis in urological surgery; *named procedures*
- US Preventive Services Task Force 41–2
- utilities, effectiveness measurement 47
- utilization costs 46
- vacuum erection devices (VED) 140
- vaginal repair, anterior 187–8
- ildenafil 136–7, 137, 138
- erectile function recovery after radical prostatectomy 140
- varicocele repair 149
- varicocelectomy
- literature search 146–7, 149
- male subfertility 146–7, 148, 149
- outcome measures 147, 149
- pregnancy 152
- scoring system 147, 148
- sperm
- concentration/motility 149, 150, 151
- morphology 149, 152
- vascular endothelial growth factor (VEGF) inhibition 343, 344, 346
- metastatic renal cell carcinoma 345, 346
- metastatic spread role 337
- vasoactive drugs
- intracavernous injection 128, 138, 139
- mechanism of action 139
- vasopressin 396
- vatalanib 344
- VEGF Trap 344
- venous thromboembolism (VTE) in urological surgery 65–70
- devices for prophylaxis 66
- guidelines for prophylaxis 65–6
- incidence 65
- literature search 67–8, 69
- outcomes 67, 68–9
- pharmacological prophylaxis 66–7, 69
- prophylaxis 65, 66–70
- recommendations 67, 68–9
- risk factors 65
- silent 65
- study selection criteria 67
- vesicoureteral reflux 382, 387
- vinblastine
- metastatic bladder cancer 323, 324, 325, 326, 327
- neo-adjuvant prior to radical prostatectomy 269, 270
- vincristine, Wilms' tumor 405
- vinflunine, metastatic bladder cancer 326
- vision internal urethrotomy (VIU), bulbar urethral strictures 164, 166–8
- vitamin E, prostate cancer prevention 240–1
- voiding dysfunction, pediatric UTIs 387, 390
- von Hippel–Lindau (VHL) tumor suppressor gene 345
- Web of Science 10
- Wilms' tumor 401–6
- anaplasia 401, 403–4, 405
- bilateral 401, 405–6
- biopsy 405, 406
- chemotherapy 404, 405–6
- chromosomal abnormalities 402–3
- compression symptoms 401
- favorable histology 403, 404, 405
- histology 401, 403–5
- outcomes 404–5
- screening 402
- staging 403–5
- surgical resection 405, 406
- unilateral 401, 405, 406
- WT2 gene 402
- zafirlukast 112
- zoledronate, metastatic prostate cancer 298

